Evidence map›Paper›PMID 40771990›Full record

ArticleCase reports in anesthesiology2025

Using Remimazolam to Generate Hemodynamically Stable Burst Suppression: A Case Report and Literature Review.

Chin Fung Kelvin Kan, Jacob E Pollard

Abstract readCase Reports
In one paragraph

Article in Case reports in anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chin Fung Kelvin KanDepartment of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-5113-0433
Jacob E PollardDepartment of Anesthesiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Remimazolam is a short-acting benzodiazepine that was approved by the United States Food and Drug Administration (FDA) in 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 min or less. Given its recent introduction, the use of remimazolam for general anesthesia and monitored anesthesia care (MAC) remains an area of ongoing investigation. In this report, we present the first documented case demonstrating that remimazolam can achieve hemodynamic stable burst suppression in a critically ill patient undergoing emergent craniectomy and aneurysm clipping. Additionally, this manuscript reviews the reported off-label applications of remimazolam in both the operating room and the intensive care unit (ICU) settings.

Identifiers

PMID40771990
PMCPMC12328058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.